The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
Aim is to treat Dyslipidemia by inhibiting PCSK9 with a novel entity
USFDA concludes inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Zydus becomes the only Indian oncology player to venture into prognosis and diagnosis along with treatment planning
The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
Saroglitazar Mg is an investigational compound in the USA/EU, undergoing Phase 2b/3 clinical trials in patients with Primary Biliary Cholangitis and Phase 2b in patients with Non- alcoholic Steatohepatitis
Subscribe To Our Newsletter & Stay Updated
